Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | GLO1 | Q04760 | 6/20 | 0.50 |
| ▸ | SLC40A1 | Q9NP59 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | LOX | P28300 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17489126 | 0.83 | L3MBTL1 (0.59) | L3MBTL1GLO1SLC40A1KDM4EPKM | |
| SCHEMBL22313300 | 0.81 | L3MBTL1 (0.58) | L3MBTL1GLO1SLC40A1KDM4EPKM | |
| SCHEMBL2371864 | 0.79 | L3MBTL1 (0.56) | L3MBTL1GLO1SLC40A1KDM4EPKM | |
| SCHEMBL762825 | 0.79 | L3MBTL1 (0.56) | L3MBTL1GLO1SLC40A1KDM4EPKM | |
| SCHEMBL29706147 | 0.79 | L3MBTL1 (0.56) | L3MBTL1GLO1SLC40A1KDM4EPKM | |
| SCHEMBL10734794 | 0.79 | L3MBTL1 (0.56) | L3MBTL1GLO1SLC40A1KDM4EPKM | |
| SCHEMBL11060698 | 0.79 | L3MBTL1 (0.56) | L3MBTL1GLO1SLC40A1KDM4EPKM | |
| SCHEMBL12000989 | 0.79 | L3MBTL1 (0.56) | L3MBTL1GLO1SLC40A1KDM4EPKM | |
| SCHEMBL17372076 | 0.79 | L3MBTL1 (0.65) | L3MBTL1GLO1SLC40A1KDM4EPKM | |
| SCHEMBL3371308 | 0.78 | L3MBTL1 (0.59) | L3MBTL1GLO1SLC40A1KAT6AMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054413-A1 | Novel 5,6-Dihydropyrazolo[3,4-E] [L,4]Diazepin-4 (IH) -One Derivatives for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| EP-1931672-A1 | NOVEL 5,6-DIHYDROPYRAZOLO[3,4-E] [L,4]DIAZEPIN-4 (IH) -ONE DERIVATIVES FOR THE TREATMENT OF ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE. | AstraZeneca AB (SE) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007040435-A1 | NOVEL 5,6-DIHYDROPYRAZOLO[3,4-E] [L,4]DIAZEPIN-4 (IH) -ONE DERIVATIVES FOR THE TREATMENT OF ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE. | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054413-A1 | Novel 5,6-Dihydropyrazolo[3,4-E] [L,4]Diazepin-4 (IH) -One Derivatives for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease | PDE4B, PDE4A, PDE12 | L3MBTL1 4535/4885GLO1 1726/4885SLC40A1 4701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.